Billion Cell Atlas adds three AI drug developers to genome research alliance

The Billion Cell Atlas represents a significant collaboration in precision medicine infrastructure, bringing together major pharmaceutical companies and specialized AI drug discovery firms around a shared genomic resource. Launched just months ago in January 2026, the alliance has already grown from its three founding members (AstraZeneca, Merck, and Eli Lilly and Company) to include Formation Bio and two additional AI-driven drug discovery partners, signaling strong industry momentum. The scale of the undertaking—over 350 million sequenced cells and upwards of six petabytes of data—positions the Atlas as the world's largest genome-wide genetic perturbation dataset, a foundation that enables member companies to move beyond traditional target discovery into understanding the mechanisms that underlie disease progression. By mapping how cells respond to genetic perturbations via CRISPR across more than 200 disease-relevant cell lines, the alliance aims to create what it describes as the most comprehensive map of human disease biology, a resource that could accelerate the identification of novel therapeutic pathways and potentially open avenues for disease reversal.